XI YUE BIOMEDICINE was established in 2009 with a research and development team. In 2015, it was officially founded, focusing on advanced technologies in stem cells, immune cells, and exosomes, dedicated to the development of regenerative formulations and new cell-based medicines. With patented serum-free stem cell cultivation technology and high-capacity, efficient immune cell cultivation technology, notable achievements have been made in autologous CIK cancer treatment, autologous adipose-derived mesenchymal stem cell (ADSC) therapy for degenerative arthritis, and allogeneic umbilical cord mesenchymal stem cell (UCSC) therapy. It has gained a leading position in the Taiwanese industry and has advanced major cell-based drug projects into clinical trial phases, contributing significantly to the field of cellular therapy technology in Taiwan